Clinical Otolaryngology | 2019
Is C‐11 Methionine PET an alternative to 18‐F FDG‐PET for identifying recurrent laryngeal cancer after radiotherapy?
Abstract
18F FDG‐PET is superior to other imaging techniques in revealing residual laryngeal cancer after radiotherapy. Unfortunately, its specificity is low, due to FDG uptake in inflammation and in anaerobic conditions. PET imaging with the amino acid‐based radiopharmaceutical C11‐methionine (MET) should be less influenced by post‐radiation conditions. The aim of this study was to investigate the potential of MET in diagnosing recurrent laryngeal cancer after radiotherapy as compared to 18F‐FDG.